These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 28814763)

  • 41. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.
    John L; Poos AM; Brobeil A; Schinke C; Huhn S; Prokoph N; Lutz R; Wagner B; Zangari M; Tirier SM; Mallm JP; Schumacher S; Vonficht D; Solé-Boldo L; Quick S; Steiger S; Przybilla MJ; Bauer K; Baumann A; Hemmer S; Rehnitz C; Lückerath C; Sachpekidis C; Mechtersheimer G; Haberkorn U; Dimitrakopoulou-Strauss A; Reichert P; Barlogie B; Müller-Tidow C; Goldschmidt H; Hillengass J; Rasche L; Haas SF; van Rhee F; Rippe K; Raab MS; Sauer S; Weinhold N
    Nat Commun; 2023 Aug; 14(1):5011. PubMed ID: 37591845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.
    Hansmann L; Han A; Penter L; Liedtke M; Davis MM
    Cancer Immunol Res; 2017 Sep; 5(9):744-754. PubMed ID: 28768640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Conundrum of Genetic "Drivers" in Benign Conditions.
    Kato S; Lippman SM; Flaherty KT; Kurzrock R
    J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
    Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
    Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
    Baum JE; Zhang P; Hoda RS; Geraghty B; Rennert H; Narula N; Fernandes HD
    Cancer Cytopathol; 2017 Jun; 125(6):398-406. PubMed ID: 28272845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
    Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
    J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
    Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses.
    Yao Q; Morgan GJ; Chim CS
    Clin Epigenetics; 2018 Dec; 10(1):158. PubMed ID: 30572945
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
    Wader KF; Fagerli UM; Børset M; Lydersen S; Hov H; Sundan A; Bofin A; Waage A
    Histopathology; 2012 Feb; 60(3):443-51. PubMed ID: 22276607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting BRAF in multiple myeloma.
    O'Donnell E; Raje NS
    Cancer Discov; 2013 Aug; 3(8):840-2. PubMed ID: 23928771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Rare Episode of Extensive Bone Marrow Necrosis in a Chemotherapy-naïve Patient with Multiple Myeloma Exhibiting
    Jeon K; Kim HJ; Kim M; Lee YK
    Ann Clin Lab Sci; 2020 Jan; 50(1):136-139. PubMed ID: 32161023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
    Katodritou E; Terpos E; North J; Kottaridis P; Verrou E; Gastari V; Chadjiaggelidou C; Sivakumaran S; Jide-Banwo S; Tsirogianni M; Kapetanos D; Zervas K; Lowdell MW
    Am J Hematol; 2011 Dec; 86(12):967-73. PubMed ID: 21919039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
    Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
    PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
    Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
    Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A.
    Elnenaei MO; Gruszka-Westwood AM; A'Hernt R; Matutes E; Sirohi B; Powles R; Catovsky D
    Haematologica; 2003 May; 88(5):529-37. PubMed ID: 12745272
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
    Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
    J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
    Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
    Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma.
    Chim CS; Liang R; Fung TK; Choi CL; Kwong YL
    J Clin Pathol; 2007 Jun; 60(6):664-9. PubMed ID: 17557868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.